COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS

(Currently amended claims showing deletions ~~by strikethrough~~ or [[double brackets]] and additions by underlining)

1 - 10 (canceled)

11 (previously presented): A human PTH analogue of the formula, [$Cha^{7,11}$, des-Met^{8}, Nle^{18}, Tyr^{34}]hPTH(1-34)NH_2 (SEQ ID NO:16), which selectively binds to the PTH2 receptor, or a pharmaceutically acceptable salt thereof.

12 - 51 (canceled)

52 (previously presented): A human PTH analogue which selectively binds to the PTH2 receptor, wherein said analogue is selected from the group consisting of

[$Cha^{7,11}$, des-Met^{8}, Nle^{18}, Tyr^{34}]hPTH(1-34)NH_2 (SEQ ID NO:16),

[$Cha^{7,11}$, D-Nle^{8}, des-Met^{18}, Tyr^{34}]hPTH(1-34)NH_2, and

[$Cha^{7,11}$, D-Nle^{8}, Nle^{18}, Tyr^{34}]hPTH(1-34)NH_2,

which selectively binds to the PTH2 receptor, or a pharmaceutically acceptable salt thereof.

53 (previously presented): A pharmaceutical composition comprising an analogue according to claim 52 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

54 (previously presented): A method of treating a medical disorder that results from altered or excessive action of the PTH2 receptor, which comprises administering to a patient in need thereof an effective amount of an analogue according to claim 52, sufficient to inhibit the activation of the PTH2 receptor of said patient.

55 (previously presented): A method according to claim 54 wherein said medical disorder is abnormal CNS functions, abnormal pancreatic functions, divergence from normal mineral metabolism and homeostasis, male infertility, abnormal blood pressure or a hypothalmic disease.